Dynamic changes in systemic immune‐inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy

Demircan, Nazım Can; Atçı, Muhammed Mustafa; Demir, Metin; Işık, Selver; Akagündüz, Baran

doi:10.1111/ajco.13784

Cited by 11 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies also confirmed that a high SII was associated with shortened progressionfree survival and increased mortality in patients with ovarian cancer (11). The SII is a predictor of the efficacy of neoadjuvant chemotherapy in patients with gastric cancer, cervical cancer, and breast cancer (12)(13)(14)(15)(16)(17). However, there are no studies on the correlation between the SII and the efficacy of neoadjuvant chemotherapy in patients with ovarian cancer.…”

Section: Introductionmentioning

confidence: 95%

Predictive value of the systemic immune-inflammation index for the efficacy of neoadjuvant chemotherapy and prognosis in patients with stage III ovarian cancer—a retrospective cohort study

Wang¹,

Yin²,

Chen³

2022

Gland Surg

View full text Add to dashboard Cite

Background: The systemic immune-inflammation index (SII) has been proven to be related to the prognoses of multiple malignant tumors. However, there are still few studies on the relationship between the SII and the effect of neoadjuvant chemotherapy in patients with ovarian cancer. It is of great significance to predict the efficacy of neoadjuvant chemotherapy in patients with ovarian cancer. Our study was aimed at determining the predictive value of the SII for the efficacy of neoadjuvant chemotherapy and prognosis in patients with stage III ovarian cancer.Methods: A total of 102 patients with stage III ovarian cancer treated in Tongji Hospital of Tongji University from January 2017 to January 2019 were retrospectively collected. According to the level of the SII before neoadjuvant chemotherapy, patients were divided into the high SII group and low SII group. We compared the effect of neoadjuvant chemotherapy between the 2 groups, and observed the progression-free survival and mortality of patients in the 2 groups after 3 years follow-up.Results: Compared with patients in the low SII group, the complete response rate of patients in the high SII group decreased significantly after neoadjuvant chemotherapy (13.73% vs. 45.10%, P=0.001), and the progressive disease rate increased (19.61% vs. 1.96%, P=0.011). The SII had certain value in predicting the inefficacy of neoadjuvant chemotherapy in patients with stage III ovarian cancer, and the area under the curve was 0.655 (95% CI: 0.548-0.762, P=0.007). The progression-free survival of patients in the high SII group was shorter than that of patients in the low SII group (P<0.001), and the overall survival rate of patients in the high SII group was lower (47.06% vs. 70.59%, P=0.016). The SII had predicting value for the postoperative death of ovarian cancer patients after neoadjuvant chemotherapy, and the area under the curve was 0.646 (95% CI: 0.537-0.756, P=0.012). Multivariate regression analysis showed that higher SII was a risk factor for death in ovarian cancer patients after neoadjuvant chemotherapy (OR: 2.700, P=0.017).Conclusions: A high SII was a predictor of inefficacy of neoadjuvant chemotherapy in patients with stage III ovarian cancer and was related to poor prognosis.

show abstract

Section: Introductionmentioning

confidence: 95%

Predictive value of the systemic immune-inflammation index for the efficacy of neoadjuvant chemotherapy and prognosis in patients with stage III ovarian cancer—a retrospective cohort study

Wang¹,

Yin²,

Chen³

2022

Gland Surg

View full text Add to dashboard Cite

show abstract

“…Patients with malignant tumors also have increased levels of inflammation throughout the body, which can promote the proliferation and metastasis of tumor cells. The SII index reflects the level of inflammation and immune function in patients with malignant tumors; thus, it has been used in the diagnosis and treatment of a variety of malignant tumors, and has been found to have high value in predicting the prognosis of cancer patients (10)(11)(12). In this study, the diagnostic value of the SII index for postoperative complications in and the long-term prognosis of CRC patients was explored, and it was found that an increased SII index score was associated with increased postoperative infectious complications and mortality.…”

Section: Discussionmentioning

confidence: 99%

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Feng¹,

Xu²,

Lin³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is one of the most common malignant tumors of the digestive tract. Surgery is the main way to cure CRC, but the postoperative complication rate and recurrence rate remain high. The systemic immune-inflammation (SII) index reflects a patient's systemic inflammatory state and immune state. Postoperative recurrence and the occurrence of complications are closely related to the inflammatory state and immune state. Thus, the SII index may have some value in predicting postoperative complications and the long-term prognosis of CRC patients, but relevant studies are currently lacking. The present study sought to examine the effect of the SII index on the postoperative complications and long-term prognosis of patients with CRC.Methods: From January 2014 to January 2017, the data of 440 patients with CRC who had been admitted to the Affiliated Hospital of Guangdong Medical University were retrospectively collected, and the patients were equally divided into the high and the low SII groups according to their preoperative SII index levels.The postoperative complication rate and postoperative progression-free survival (PFS) and mortality between the 2 groups were compared.Results: Compared to the low SII group, the incidence of postoperative infection in the high SII group was significantly increased (15.45% vs. 9.09%, P=0.042), mortality was significantly increased at 5 years postoperatively (20.91% vs. 7.27%, P<0.001), and PFS was significantly shortened (P<0.001). The SII index had certain predictive value for postoperative infection in CRC patients, and the area under the curve (AUC) was 0.645 [95% confidence interval (CI): 0.559-0.731, P=0.001]. The SII index also had certain predictive value for the progression of CRC patients within 5 years of surgery, and the AUC was 0.670 (95% CI: 0.610-0.729, P<0.001). Additionally, the SII index had certain predictive value for death within 5 years of surgery in patients with CRC, and the AUC was 0.660 (95% CI: 0.593-0.726, P<0.001). CRC patients with postoperative infection had a significantly shorter PFS period than those who did not develop postoperative infection (P=0.029). Conclusions:The SII index has certain predictive value for the diagnosis of postoperative infectious complications and the long-term prognosis of CRC patients.

show abstract

“…PNI and its variations had been proven to predict prognosis of breast cancer and lung cancer [23,24]. SII and its variations also had prognosis prediction in gastric or gastroesophageal junction cancer and non-small-cell lung cancer [25,26].…”

Section: Discussionmentioning

confidence: 99%

Efficacy prediction of systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) in breast cancer patients and their variations after Neoadjuvant chemotherapy

Jin

Xue³

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: The objective of this study is to evaluate the efficacy prediction values of systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) in breast cancer patients who received neoadjuvant chemotherapy.Methods: We registered a retrospective study include 72 breast cancer patients between February 2020 and January 2022. All patients had axillary lymph node metastasis receiving neoadjuvant therapy. Calculating PNI, SII before and after therapy were examined through blood routine. Chi-square test was used to compare the clinicopathological and laboratory parameters between groups. Using the logistic regression analysis to evaluate the prognosis values of the factors.Results: 18 patients (25%) achieved pathologic complete response (pCR) after neoadjuvant therapy. The pCR rate of breast patients had significant relationship with ER, PR, HER-2, molecular subgroup, tumor size, vascular invasion, nerve invasion, N stage, clinical stage and chemotherapy regimen. Low ΔPNI, high ΔSII and higher ΔPNI-ΔSII score values had better prediction of therapeutic effect, especially the ΔPNI-ΔSII score.Conclusion: The ΔPNI-ΔSII score may be an effective efficacy prediction index in breast cancer patients receiving neoadjuvant chemotherapy, which can help to identify high-risk groups and efficacy evaluation.

show abstract

Dynamic changes in systemic immune‐inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy

Cited by 11 publications

References 48 publications

Predictive value of the systemic immune-inflammation index for the efficacy of neoadjuvant chemotherapy and prognosis in patients with stage III ovarian cancer—a retrospective cohort study

Predictive value of the systemic immune-inflammation index for the efficacy of neoadjuvant chemotherapy and prognosis in patients with stage III ovarian cancer—a retrospective cohort study

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Efficacy prediction of systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) in breast cancer patients and their variations after Neoadjuvant chemotherapy

Contact Info

Product

Resources

About